Amid The Lipitor Scuffle, What’s Next For Crestor?
Expiration of the Lipitor patent puts tremendous pressure on AstraZeneca’s bestselling statin, Crestor, which accounts for 20% of total revenues. AstraZeneca insists the drug’s value proposition will enable it to withstand the onslaught, but analysts expect a gradual chipping away at market share.
You may also be interested in...
Generic Crestor Marks The End Of An Era, Should Quickly Outperform PCSK9s
Allergan PLC's generic version of AstraZeneca PLC's blockbuster statin Crestor (rosuvastatin) is likely to need only a few weeks on the US market to surpass total sales of the PCSK9 inhibitors to date.
Crestor ANDAs May Seek Approval For Unpatented Uses, Appeals Court Rules
The Federal Circuit ruled that AstraZeneca cannot claim infringement of unpatented uses of rosuvastatin; the court affirmed the validity of section viii labeling carve-outs.
AstraZeneca Goes Virtual In Neuroscience R&D As Part Of Workforce Reduction
AstraZeneca is to slash 12% of its workforce in the next three years, as the company forecasts declining revenues in 2012 because of its steep patent cliff, government pricing interventions and R&D pipeline failures.